Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 4/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22282077 | 0.92 | MAOB (0.42) | MAOBDAOKDM1AMAOAHRH3 | |
| SCHEMBL23868234 | 0.86 | MAOB (0.40) | MAOBDAOKDM1AMAOAHRH3 | |
| SCHEMBL4893159 | 0.85 | CYP2D6 (0.41) | CYP2D6CYP2C19HTTHRH1KDM4E | |
| SCHEMBL14451172 | 0.85 | CYP2D6 (0.41) | CYP2D6CYP2C19HTTHRH1KDM4E | |
| SCHEMBL11572427 | 0.85 | — | — | |
| SCHEMBL18270112 | 0.85 | MAOB (0.39) | MAOBDAOKDM1AMAOAHRH3 | |
| SCHEMBL20331224 | 0.82 | MAOB (0.40) | MAOBDAOKDM1AMAOAHRH3 | |
| SCHEMBL24753347 | 0.82 | GNAI3 (0.41) | MAOBMAOATLR7HTT | |
| SCHEMBL19605014 | 0.81 | MAOB (0.39) | MAOBDAOKDM1AMAOAHRH3 | |
| SCHEMBL12572933 | 0.81 | HTR7 (0.49) | MAOBDAOKDM1AMAOACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4272825-A2 | MTORC MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230002382-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUNDS | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20220119396-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-21 | — | — | US | disclosed |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | AMGEN INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-11021492-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210002300-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2021-01-07 | — | — | US | disclosed |
| WO-2020154447-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC | 2020-02-20 | — | — | US | disclosed |
| US-9314468-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9290507-B2 | B-RAF kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-22 | — | — | US | disclosed |
| US-9290507-B2 | B-RAF kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-22 | — | — | US | disclosed |
| US-8865703-B2 | Pyridyltriazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-20130225562-A1 | PYRIDYLTRIAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130190286-A1 | B-RAF KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| US-20130172330-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8338448-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100029634-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119396-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | MAOB 2614/4885DAO 1235/4885KDM1A 1505/4885 |
| US-20130225562-A1 | PYRIDYLTRIAZOLES | CCNT1, CCNT2, MKI67 | MAOB 260/4885DAO 4115/4885KDM1A 997/4885 |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | MKI67, CCNI, CDKN1A | MAOB 2303/4885DAO 2783/4885KDM1A 136/4885 |
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | MAOB 2614/4885DAO 1235/4885KDM1A 1505/4885 |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | TYR, TYRO3, TH | MAOB 110/4885DAO 39/4885KDM1A 1367/4885 |
| US-20210002300-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | MAOB 4449/4885DAO 4461/4885KDM1A 3869/4885 |
| US-20230002382-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUNDS | KRAS, NRAS, HRAS | MAOB 4725/4885DAO 4674/4885KDM1A 3893/4885 |
| US-20130172330-A1 | Chemokine Receptor Modulators | CCR5, CXCR4, ACKR3 | MAOB 4533/4885DAO 4659/4885KDM1A 4652/4885 |
| US-20130190286-A1 | B-RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MAOB 662/4885DAO 2387/4885KDM1A 1545/4885 |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | RET, BRAF, ROR1 | MAOB 2630/4885DAO 1253/4885KDM1A 1452/4885 |
| US-20100029634-A1 | Chemokine Receptor Modulators | CCR5, CXCR4, ACKR3 | MAOB 4533/4885DAO 4659/4885KDM1A 4652/4885 |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | MCL1, BCL9, BCL2L1 | MAOB 4311/4885DAO 4170/4885KDM1A 1242/4885 |
| US-11021492-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | MAOB 4449/4885DAO 4461/4885KDM1A 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.